For LGBTQ+ ophthalmologists, truth has often had consequencesJune 2nd 2023
For Michael A. Puente Jr., MD, being open about himself and advocating for an overlooked community hasn’t always been as easy as it is today. Progress has been incremental, but he is optimistic about the state of ophthalmology for LGBTQ+ physicians and patients.
Nacuity Pharmaceuticals achieves target enrollment for Phase 1/2 clinical trial of NPI-001 for treatment of retinitis pigmentosa associated with Usher syndromeJune 1st 2023
According to the company, the Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH, with interim efficacy data anticipated by the end of the year.
Coave Therapeutics announces positive data from Phase I/II clinical trial of CTx-PDE6bMay 31st 2023
According to the company, CTx-PDE6b in patients with retinitis pigmentosa caused by bi-allelic mutations in PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile.
New FDA blood donor recommendations could ease restrictions on cornea donations from gay, bisexual menMay 31st 2023
The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities, such as transgender women or nonbinary donors, will be impacted.
Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophyMay 29th 2023
Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
Oxurion reaches enrollment target in clinical trial for THR-149 in DMEMay 26th 2023
According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for patients who respond suboptimally to anti-VEGF, the standard of care for treatment of DME.
Comparing 6-weekly and 12-weekly dose IVMP regimens for treating active thyroid-associated orbitopathyMay 26th 2023
While the 6-weekly regimen was less effective in improving the clinical activity score or exophthalmos than the higher dose regimen, it is an acceptable treatment choice for patients with marginal or lower clinical activity scores.
AI used to advance drug delivery system for glaucoma and other chronic diseasesMay 25th 2023
The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.
Allgenesis announces preliminary safety and efficacy data from AG-73305 Phase 2a trial for treatment of DMEMay 25th 2023
According to the company, AG-73305 was found to be safe and tolerable with no severe adverse effects after a single intravitreal injection of 0.5 mg and 1 mg in patients diagnosed with diabetic macular edema.